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 ABSTRACT 
Purpose: The goal of this study was to measure estrogen receptor (ER) concentration in 
the endometrium and myometrium using 16α-[18F]fluoro-17β-estradiol (FES) PET and 
to investigate the relationship between changes in these parameters with the menstrual 
cycle and endogenous estrogen levels.  Methods: Sixteen female healthy volunteers 
were included in this study.  After blood sampling to measure endogenous estrogen 
level, FES-PET image was acquired 60 min postinjection of FES.  After whole-body 
imaging of FES-PET, averaged standardized uptake value (SUV) in the endometrium 
and myometrium were measured, and the relationship between FES uptake and 
menstrual cycle or endogenous estrogen level was evaluated.  Results: Endometrial 
SUV was significantly higher in the proliferative phase than in the secretory phase (6.03 
±1.05 vs. 3.97 ± 1.29, p = 0.022).  In contrast, there was no significant difference in 
myometrial SUV when comparing the proliferative and secretory phases (p = 0.23).  
Further, there was no correlation between SUV and endogenous estrogen level in the 
proliferative phase.  Conclusions: The change of ER concentration relative to 
menstrual cycle as characterized by FES-PET was consistent with those from previous 
report using immunohistochemical technique.  These data suggest FES-PET is a 
feasible noninvasive method of characterizing changes in ER concentration. 
3 
 INTRODUCTION 
16α-[18F]fluoro-17β-estradiol (FES) is a radiopharmaceutical that binds to the 
estrogen receptor (ER) and expresses the existence of ER [1].  FES can help 
characterize the diagnosis and efficacy of hormonal therapy in patients with ER-positive 
breast cancer [2-6].  Indeed, Mintun et al. [2] reported that in vivo uptake of FES in 
primary breast carcinoma correlates with in vitro measurements of ER concentration 
and thereby represents a noninvasive quantitative measurement of ER in breast 
carcinoma.  Although several studies reported the expression of ER in many organs 
other than breast using immunohistochemistry [7], such findings has not known yet in 
human study even in normal ER-rich tissue like endometrium or myometrium.  
Because FES is expected to be a good tracer to reveal the change of ER concentration in 
normal tissue as well as in disease, normal control data should be required.  In 
immunohistochemical studies, the relationships between the level of ER and menstrual 
cycle in endometrium and myometrium are reported as follows [8-17]; In endometrium, 
the level of ER increase from early- to late proliferative phase, then fell down in 
secretory phase.  In myometrium, the cyclical change of ER varies in different layers.  
The inner part of the myometirum (stratum subvasculare) adjacent to endometrium 
shows the same behavior as the endometrium does.  On the other hand, the outer part 
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 of the myometirum (stratum vasculare and supuravasculare) shows the constant ER 
expression through the whole menstrual cycle.  It is well known that the endogenous 
estrogen level alters during menstrual cycle, which has two peaks in late proliferative 
and mid secretory phase and thus, the effect of estrogen level on FES uptake should also 
be studied before clinical application.  Therefore, the goal of this study was to measure 
ER concentration in the endometrium and myometrium using FES-PET and to 
investigate the relationship between changes in these parameters with the menstrual 
cycle and the endogenous estrogen level in healthy volunteers. 
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 MATERIALS AND METHODS 
Subjects 
Sixteen female normal volunteers were included in this study.  Participant age 
range was 21 to 28 years old (23.6 ± 2.2 yrs; mean ± SD).  Medical interviews, 
encompassing previous malignancy and gynecological surgery, menstrual state and 
cycle, and the last menstrual period, were conducted in all subjects.  Written informed 
consent was obtained from all subjects participating in this study, which was approved 
by the institutional review board of University of Fukui Hospital. 
 
Synthesis of FES 
FES synthesis was performed according to the method of Kiesewetter et al. [1] 
with modifications as reported by Mori et al. [18] in detail.  A cassette-type automatic 
[18F]fluorodeoxyglucose (FDG) synthesizer (TRACERlab MXFDG, GE Medical Systems, 
Milwaukee, WI) that was modified for the synthesis of FES was utilized and 
fluorination, two-step hydrolysis, and neutralization were performed under the 
appropriate condition to synthesize FES.  After the final purification, the 
radiochemical purity was greater than 99% and the yield was 42.4 ± 3.2 % (EOB).  
The specific activity calculated by the analytical HPLC system was more than 111 
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 GBq/μmol. 
 
PET Imaging 
All subjects fasted more than 4 hours prior to FES-PET examination to eliminate 
the excretion of FES from the hepatobiliary system and the gastro-intestinal tract, which 
would otherwise interfere with image interpretation in the pelvic space.  Three ml of 
blood was obtained just before FES injection to measure the endogenous estrogen level 
(estradiol, E2).  FES-PET data acquisition started 60 min after the injection of 185 
MBq of FES.  Emission scans were performed for 3 min in the pelvic portion (2 bed 
positions) and 2 min in remaining positions (5 bed positions) to cover the area from the 
head to the inguinal region.  Postinjection transmission scans for 2 min at pelvis and 1 
min in other parts were performed after the emission scans for attenuation correction.  
The acquired data were reconstructed using an iterative reconstruction method with 14 
subsets and 2 iterations.  The reconstructed image was converted to standardized 
uptake value (SUV) image according to the subject’s body weight and net injected dose 
for the data analysis. 
 
MRI Imaging 
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 All subjects underwent MRI examination on the same day of FES-PET or on one 
day before FES-PET to obtain positional information regarding the endometrium and 
myometrium.  T1- and T2-weighed images (WI) in the transaxial plane and T2-WI in 
the sagittal plane were acquired with 1.5-Tesla superconducting MRI system (Signa, GE 
Medical Systems, Milwaukee, WI).  The imaging sequence of T1-WI and T2-WI was 
533/8 and 4700/90 (TR/TE, unit;msec), respectively. 
 
Data Analysis 
On mid-sagittal image of FES-PET, circular regions of interest (ROIs: 8 mm in 
diameter) were placed using guidance by T2-WI of MRI in the sagittal plane.  By 
comparing FES-PET and MRI visually, endometrium which usually has high uptake of 
FES compared with myometrium was identified.  Myometrium was defined as the 
faint FES uptake area surrounding the endometrium.  Three ROIs were placed on the 
endometrium and 9 were placed on the myometrium shown in Figure 1.  The averaged 
SUV in endometrium and myometrium were plotted against the days from the onset of 
menses and the endogenous estrogen level. 
In this study, the menstrual cycle was divided into 2 groups because of the limited 
number of subjects.  Those participations who were 6 to 14 days after the onset of 
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 menses were defined as being in the proliferative phase and those who were 15 to 28 
days from the onset of menses were defined as being in the secretory phase.  SUV 
between these 2 phases were compared in the endometrium and myometrium.  
Nonparametric Mann-Whitney U-test was used for statistical comparisons.  Spearman 
nonparametric correlation analysis was performed to analyze the relationship between 
SUV in endometrium and SUV in myometrium and E2.  In each statistical analysis, p 
< 0.05 was considered to represent statistical significance. 
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 RESULTS 
Characteristics of the subjects and summary of the results are shown in Table 1. 
One subject had irregular menstrual cycle and was excluded from the analysis of 
the relationship between FES uptake and menstrual cycle.  From the definition of 
menstrual cycle stated in the section of data analysis, 6 subjects were classified as being 
in the proliferative phase and 7 were classified as being in the secretory phase.  Two 
subjects were in the menstrual phase and were also excluded from this analysis.  In the 
analysis of the relationship between FES uptake and E2 level, no subjects were 
excluded. 
Figure 2A shows the relationship between endometrial SUV and the menstrual 
cycle.  SUV was significantly higher in the proliferative phase than in the secretory 
phase (6.03 ± 1.05 vs. 3.97 ± 1.29, p = 0.022). 
The relationship between myometrial SUV and the menstrual cycle is illustrated in 
Figure 2B.  No significant difference in SUV was noted when comparing the 
proliferative and secretory phase (2.75 ± 0.22 vs. 2.53 ± 0.37, p = 0.23). 
Further, there was no relationship between FES uptake and E2 level in the 
endometrium (Figure 3A) or myometrium (Figure 3B) in the proliferative phase. 
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 DISCUSSION 
Physiological FES uptake in the endometrium is affected by the menstrual cycle 
secondary to changes in endogenous estrogen level in healthy women.  However, the 
present study demonstrated that endometrial SUV was not directly correlated with 
plasma E2 level or FES uptake in the myometrium.  Yoo et al. [19] reported that FES 
preferentially binds the ERα subtype with 6.3-fold higher affinity than that for ERβ.  
Further, the uterus is one of the target organs of E2 and expresses both ERα and ERβ.  
ERα predominates in the uterus, breast, kidney, liver, and heart, whereas tissues that 
have high ERβ levels include prostate, testes, ovaries, gastrointestinal tract, lung, 
bladder, hematopoietic and central nervous systems.  Many tissues contain both ERα 
and ERβ, such as breast, epididymis, thyroid, adrenal, bone.  Wang et al. used 
immunohistochemistry to demonstrate that the myometrium and leiomyomas have 
ERα-dominant expression [20].  These results suggested that uterine ER expression is 
a good target for study with FES-PET.  However, physiological FES uptake in the 
uterus of healthy women remains unclear, and may vary with the menstrual cycle 
observed in FDG-PET [21]. 
Several investigators have used immunohistochemistry to characterize the 
relationship between ER expression and menstrual cycle measured in the endometrium 
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 [8-17] and myometrium [9-16].  In these reports, endometrial ER concentration in the 
proliferative phase was higher than that in the secretory phase, which is consistent with 
results from the present study.  Further, several studies have reported a significant 
difference between myometrial ER concentration in the proliferative phase and the 
secretory phase.  By contrast, the present study showed no significant difference in 
myometrial FES uptake when comparing the proliferative phase and secretory phase.  
This finding is supported by some papers [14 – 16].  Noe and Vienonen reported [15, 
16] that in the myometirum ERα was regulated in the layer adjacent to the endometrium 
in an endometrium-like pattern during the menstrual cycle, whereas expression pattern 
in the outer part of the myometrium were more stable. In the studies which showed a 
significant difference between myometrial ER concentration in the proliferative phase 
and the secretory phase, only the myometrium immediately underlying the endometrium 
was analyzed as the representative of the whole uterine muscular wall [9-11].  In the 
present study, placed ROI on the myometrium which surrounded endometrial ROI 
rather evaluated the outer part of the myometirum because of the limited spatial 
resolution. 
In this study, there was no significant relationship between FES uptake and E2 
even in the proliferative phase.  A previous study reported that a large concentration of 
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 endometrial ER in the late proliferative phase correlates with the plasma estradiol surge 
[22].  Further, Levy et al. reported that a significant correlation was observed between 
ER concentration and E2 in the proliferative phase [8].  In the present study, there was 
a trend toward a relationship between E2 and SUV in the endometrium in the 
proliferative phase (p = 0.09), but the difference did not reach the level of statistical 
significance.  Repetition of the present study with a large population size may result in 
data consistent with those reported by Levy et al. 
The relationship between ER concentration in the myometrium and endogenous 
estrogen level demonstrated no statistical significance.  FES uptake in the myometrium 
was almost constant through the entire menstrual cycle and may be independent from 
the change of endogenous estrogen level in healthy volunteers. 
Although FES represents the level of unoccupied ER and ER measured with 
immunohistochemistry represents total ER, our results and the previous reports showed 
the same behavior.  Katzenellenbogen et al. reported [23] that the FES uptake in the 
uterus was suppressed by the coinjection of high dose of estradiol or the tamoxifen 
pretreatment in the rat.  But in proliferative phase, although total ER and occupied ER 
by endogenous estrogen in the endometrium will increase, the proportion of unoccupied 
ER measured with FES will not change.  In secretory phase, the opposite phenomenon 
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 will occur and the proportion of unoccupied ER will not also change.  Therefore, it is 
speculated the behavior of total ER and unoccupied ER will be similar.  In 
myometrium, total and unoccupied ER in proliferative phase did not change when the 
endogenous estrogen increased.  The proportion of occupied ER against total ER may 
be enough small although further examination will be required. 
FES has been used for the evaluation of breast tumors [2-6] and may also have 
clinical application in patients with uterine endometrium-related gynecological diseases 
[24, 25].  Indeed, Okazawa et al. reported [25] that the combination of FDG- and 
FES-PET improved the diagnostic accuracy in various uterine endometrium-related 
gynecological diseases including uterine endometrial cancer, adenomyosis, and 
endometrial hyperplasia.  For the assessment of FES uptake, SUV or lesion to normal 
ratio (L/N) will be feasible.  The present study demonstrated that FES uptake in the 
endometrium varied with the menstrual cycle, whereas myometrial FES uptake was 
stable throughout the entire menstrual cycle.  These data suggest that the myometirum 
may serve as a good internal control during FES studies of other organ systems and the 
menstrual cycle should be taken account for when the endometrium was considered for 
an internal control. 
 
14 
 CONCLUSION 
The change of ER concentration relative to menstrual cycle as characterized by 
FES was consistent with those from previous report using immunohistochemical 
technique.  Further, these data suggest that FES-PET is a feasible noninvasive method 
of characterizing changes in ER concentration. 
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 FIGURE LEGENDS 
 
Figure 1 Sagittal PET image of [18F]-FES distribution in a healthy woman (left) and 
representative regions of interest (ROIs) placed on the endometrium (white 
circles) and myometrium (dotted circles) (right).  Image was acquired 60 
min postinjection of 185 MBq of FES. 
Figure 2 Changes in FES uptake in the uterus during the menstrual cycle.  
Endometrial FES uptake (A) was significantly higher in the proliferative 
phase (closed circle) than in the secretory phase (open circle).  By contrast, 
myometrial FES uptake (B) was similar when comparing the two phases. 
Figure 3 Relationship between FES uptake and endogenous estrogen level.  Linear 
regression analysis (solid line) was performed only in the proliferative 
phase (closed circle).  No significant linear correlation was observed in the 
endometrium (A) (y = 0.05 x + 2.95, r2 = 0.56, p = 0.09) or the 
myometirum (B) (y = 0.006 x + 2.37, r2 = 0.20, p = 0.38).  Open circle 
represents SUV in the proliferative phase and open square represents SUV 
in the menstrual phase. 
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